Ovid Therapeutics Inc
NASDAQ:OVID
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.255
1.84
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Ovid Therapeutics Inc
NASDAQ:OVID
|
110.3m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
393.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.7B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.7B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.4B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Ovid Therapeutics Inc
Glance View
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 44 full-time employees. The company went IPO on 2017-05-05. The firm is focused on developing medicines for patients and families living with epilepsies, seizure-related disorders and neurological disorders. The Company’s programs include OV329 (GABA aminotransferase inhibitor), OV350, OV882, and OV815 and OV825. OV329 (GABA aminotransferase inhibitor) is a next-generation GABA aminotransferase inhibitor being developed for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms. OV329 functions by substantially reducing the activity of GABA aminotransferase (GABA-AT), a key enzyme responsible for the degradation of the brain’s major inhibitory neurotransmitter, GABA. OV350 is a small molecule that directly activates the KCC2 transporter, which is an important channel in seizure control. OV882, which is a short hairpin RNA (shRNA-551) for Angelman syndrome. OV815, which is a genetic therapy approach for KIF1A-associated neurological disorders.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Ovid Therapeutics Inc is -618.3%, which is above its 3-year median of -14 685.9%.
Over the last 3 years, Ovid Therapeutics Inc’s Operating Margin has increased from -4 985.7% to -618.3%. During this period, it reached a low of -54 200% on Mar 31, 2023 and a high of -618.3% on Sep 30, 2025.